A retrospective study based in the Netherlands found an apparent genetic link between blue eye color and poorer survival in patients with uveal melanoma—including a greater incidence of high-risk tumor development in patients with light eyes than in those with darker eyes—though larger, more diverse studies are needed to confirm these findings.
Of Interest
Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
In a pooled analysis of long-term outcomes reported in the Journal of Clinical Oncology, Long et al found that nivolumab plus ipilimumab was associated with better overall survival vs nivolumab monotherapy in immune checkpoint inhibitor treatment–naive patients with unresectable or metastatic melanoma.
Cutaneous Melanoma Incidence Declining Among Pediatric, AYA Patients
The incidence of cutaneous melanoma is generally declining among pediatric and adolescent and young adult (AYA) patients in the United States, according to research published in the Journal of the American Academy of Dermatology.
Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction
Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.